Back to top
more

CanFite Biopharma (CANF)

(Delayed Data from AMEX)

$2.09 USD

2.09
3,218

+0.06 (2.96%)

Updated May 3, 2024 03:59 PM ET

After-Market: $2.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CANF

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Can-Fite Biopharma Ltd [CANF]

Reports for Purchase

Showing records 21 - 40 ( 216 total )

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 21

01/12/2023

Company Report

Pages: 5

Neutral: Effects 1:10 Reverse Stock Split & Raises $7.5 Million

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 22

01/03/2023

Company Report

Pages: 6

Lowering to Neutral from Buy Ahead of Reverse Split

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 23

12/28/2022

Company Report

Pages: 6

BUY-Rated: Namodenoson Advances

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 24

12/12/2022

Company Report

Pages: 6

BUY-Rated: Raising Our Target from $5.0 to $8.0

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 25

11/29/2022

Company Report

Pages: 6

BUY-Rated: Third Quarter Results - $10.8M in Cash

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 26

10/25/2022

Company Report

Pages: 6

BUY-Rated: Can-Fite announces poster presentation highlighting complete response induced by Namodenoson at the American Association for the Study of Liver Diseases

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 27

10/14/2022

Company Report

Pages: 6

BUY-Rated: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 28

09/21/2022

Company Report

Pages: 6

BUY-Rated: Webinar at 11:00 AM

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 29

09/13/2022

Company Report

Pages: 4

New COMFORT Piclidenoson Results Presented at EADV; Reiterate Buy and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 30

09/12/2022

Company Report

Pages: 6

BUY-Rated: New Data at EADV

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 31

09/01/2022

Company Report

Pages: 6

BUY-Rated: 2nd Quarter Results

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 32

08/23/2022

Company Report

Pages: 6

BUY-Rated: Namodenoson Approved for Compassionate Use Romania for HCC

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 33

08/22/2022

Company Report

Pages: 6

BUY-Rated: European Academy of Dermatology and Venerology Congress

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 34

07/11/2022

Company Report

Pages: 6

BUY-Rated: Can-Fite to submit FDA & EMA Registration Plans for Piclidenoson - Severe Psoriasis

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 35

06/29/2022

Company Report

Pages: 6

BUY-Rated: COMFORT Pivotal Study Meets Its Primary Endpoint

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 36

06/29/2022

Company Report

Pages: 4

Positive Top-Line Results From COMFORT Position Piclidenoson For Pivotal Study; Reiterate Buy and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 37

05/26/2022

Company Report

Pages: 6

BUY-Rated: Reports 1Q22 Results

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 38

04/06/2022

Company Report

Pages: 4

Namodenoson and Piclidenoson Continue to Achieve Milestones; Reiterate Buy and $5 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 39

03/25/2022

Company Report

Pages: 6

BUY-Rated: Top-Line Psoriasis Data is Coming

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: Can-Fite Biopharma Ltd

Industry: Medical - Drugs

Record: 40

01/31/2022

Company Report

Pages: 6

BUY-Rated: Nash Trial Begins - First Patient Enrolled

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party